Research Analysts’ Weekly Ratings Changes for Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals (NASDAQ: CRNX) recently received a number of ratings updates from brokerages and research firms:

• 5/11/2026 – Crinetics Pharmaceuticals had its price target lowered by Oppenheimer Holdings, Inc. from $87.00 to $84.00. They now have an “outperform” rating on the stock.
• 5/9/2026 – Crinetics Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 5/8/2026 – Crinetics Pharmaceuticals had its price target lowered by Citizens Jmp from $97.00 to $95.00. They now have a “market outperform” rating on the stock.
• 4/28/2026 – Crinetics Pharmaceuticals had its price target raised by Citizens Jmp from $96.00 to $97.00. They now have a “market outperform” rating on the stock.
• 4/20/2026 – Crinetics Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/28/2026 – Crinetics Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In related news, CFO Tobin Schilke sold 6,713 shares of Crinetics Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $39.67, for a total transaction of $266,304.71. Following the completion of the sale, the chief financial officer owned 78,121 shares of the company’s stock, valued at approximately $3,099,060.07. The trade was a 7.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Richard Scott Struthers sold 21,981 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total transaction of $821,429.97. Following the sale, the chief executive officer directly owned 404,778 shares of the company’s stock, valued at $15,126,553.86. The trade was a 5.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 142,380 shares of company stock valued at $5,569,475. 3.80% of the stock is owned by company insiders.

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.